Diabetes is a complex and multifactorial metabolic disease characterized by the autoimmune ‎destruction of pancreatic beta cells or a combination of peripheral insulin resistance and impaired ‎insulin secretion. Current therapeutic approaches are not curative and have their complications. Recently, stem cell-based therapies have emerged as a promising approach with the potential to restore ‎normoglycemia and beta cell function, reverse diabetes, achieve long-term glycemic control, and ‎prevent complications. ‎Various stem cell sources are being investigated to find a potential solution for  ‎manufacturing unlimited transplantable insulin-secreting cells. Significant progress has been made in preclinical studies and the generation of islet-like ‎endocrine clusters or organoids. However, the clinical translation of these cell therapies is still in the ‎early stages. New strategies such as gene editing and tissue engineering may improve the safety and efficacy of stem cell-derived beta or progenitor cell transplantation. This review discusses the current state of islet transplantation, different cell-based ‎therapies, and their potential for clinical translation, with a major focus on pancreatic organoids and ‎associated technologies.‎